Allogeneic Bone Marrow-Derived Mscs
Bone Marrow Failure Syndrome
Explore 20 assets in Bone Marrow Failure Syndrome →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Burnasyan Federal Medical Biophysical Center
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02145923CT.gov Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bone Marrow Failure Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Allogeneic Bone Marrow-Derived Mscs (this asset) | Burnasyan Federal Medical Biophysical Center | P1/2 | CCC · 48 |
| Fludarabine | Fred Hutchinson Cancer Center | P2/3 | BBB |
| Cyclophosphamide | Memorial Sloan Kettering Cancer Center | P2/3 | BBB |
| Thiotepa | Fred Hutchinson Cancer Center | P2 | BB |
| Alemtuzumab | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P2/3 | BB |
| Busulfanum | Memorial Sloan Kettering Cancer Center | P2/3 | BB |
| Melphalan | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P2 | B |
| Treosulfan | Fred Hutchinson Cancer Center | P2 | B |
| Horse Anti-Thymocyte Globulin | New York Medical College | P2/3 | B |
+22 more in the Bone Marrow Failure Syndrome cohort
Other indications for Allogeneic Bone Marrow-Derived Mscs
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lumbar Disk Degenerative Disorder | — | P2/3 | CCC · 54 |
| Bipolar Depression | — | P1 | CC · 43 |
| Parkinson Disease | — | P1 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Allogeneic Bone Marrow-Derived Mscs in Bone Marrow Failure Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/allogeneic-bone-marrow-derived-mscs-bone-marrow-failure-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →